Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis.

Date publication

février 2025

Journal

The Journal of clinical endocrinology and metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HUET Frédéric

Tous les auteurs :
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin ML, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud MC, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel AS, Sermet-Gaudelus I,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39977216

Résumé

Highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), herald a new era in therapeutic strategy of cystic fibrosis (CF). ETI impact on glucose tolerance remains controversial.

Mots clés

CFTR, Cystic Fibrosis, Elexacaftor/tezacaftor/ivacaftor, adolescents, glucose tolerance, oral glucose tolerance testing

Référence

J Clin Endocrinol Metab. 2025 02 20;: